Cargando…

Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials

BACKGROUND: Antiarrhythmic drugs (AADs) are frequently prescribed following catheter ablation (CA) for atrial fibrillation (AF). However, to date, there is a lack of large-scale, multicenter controlled studies that have confirmed the efficacy of AADs in reducing the incidence of late recurrence of A...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Gang, Li, Guangling, Zhang, Demei, Wang, Xiaomei, Guo, Xueya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397410/
https://www.ncbi.nlm.nih.gov/pubmed/37547248
http://dx.doi.org/10.3389/fcvm.2023.1071950
_version_ 1785083906192572416
author Chen, Gang
Li, Guangling
Zhang, Demei
Wang, Xiaomei
Guo, Xueya
author_facet Chen, Gang
Li, Guangling
Zhang, Demei
Wang, Xiaomei
Guo, Xueya
author_sort Chen, Gang
collection PubMed
description BACKGROUND: Antiarrhythmic drugs (AADs) are frequently prescribed following catheter ablation (CA) for atrial fibrillation (AF). However, to date, there is a lack of large-scale, multicenter controlled studies that have confirmed the efficacy of AADs in reducing the incidence of late recurrence of AF after CA. Furthermore, the optimal duration of short-term use of AADs after CA remains a controversial topic. METHODS: PubMed, Embase, Cochrane Library, CNKI, and ClinicalTrials.gov were searched until April 25, 2022. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of blanking period AADs in predicting both early and late recurrence of AF. In addition, Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess the quality of evidence in this meta-analysis. RESULTS: 12 RCTs with 3,625 patients were included in this meta-analysis. Short-term use of AADs after AF ablation reduced the risk of early recurrence of AF compared with the no-AADs group. In the subgroup analysis of AADs use time, it was found that only using AADs for more than 2 months can reduce the early recurrence of AF after CA. However, when compared with the no-AADs group, short-term use of AADs after CA did not reduce the incidence of late recurrence of AF. CONCLUSIONS: Short-term use of AADs (more than 2 months) can reduce the early recurrence but not the late recurrence of AF after CA.
format Online
Article
Text
id pubmed-10397410
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103974102023-08-04 Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials Chen, Gang Li, Guangling Zhang, Demei Wang, Xiaomei Guo, Xueya Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Antiarrhythmic drugs (AADs) are frequently prescribed following catheter ablation (CA) for atrial fibrillation (AF). However, to date, there is a lack of large-scale, multicenter controlled studies that have confirmed the efficacy of AADs in reducing the incidence of late recurrence of AF after CA. Furthermore, the optimal duration of short-term use of AADs after CA remains a controversial topic. METHODS: PubMed, Embase, Cochrane Library, CNKI, and ClinicalTrials.gov were searched until April 25, 2022. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of blanking period AADs in predicting both early and late recurrence of AF. In addition, Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess the quality of evidence in this meta-analysis. RESULTS: 12 RCTs with 3,625 patients were included in this meta-analysis. Short-term use of AADs after AF ablation reduced the risk of early recurrence of AF compared with the no-AADs group. In the subgroup analysis of AADs use time, it was found that only using AADs for more than 2 months can reduce the early recurrence of AF after CA. However, when compared with the no-AADs group, short-term use of AADs after CA did not reduce the incidence of late recurrence of AF. CONCLUSIONS: Short-term use of AADs (more than 2 months) can reduce the early recurrence but not the late recurrence of AF after CA. Frontiers Media S.A. 2023-07-20 /pmc/articles/PMC10397410/ /pubmed/37547248 http://dx.doi.org/10.3389/fcvm.2023.1071950 Text en © 2023 Chen, Li, Zhang, Wang and Guo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Chen, Gang
Li, Guangling
Zhang, Demei
Wang, Xiaomei
Guo, Xueya
Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials
title Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials
title_full Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials
title_fullStr Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials
title_full_unstemmed Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials
title_short Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials
title_sort blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397410/
https://www.ncbi.nlm.nih.gov/pubmed/37547248
http://dx.doi.org/10.3389/fcvm.2023.1071950
work_keys_str_mv AT chengang blankingperiodantiarrhythmicdrugsaftercatheterablationforatrialfibrillationametaanalysisofrandomizedcontrolledtrials
AT liguangling blankingperiodantiarrhythmicdrugsaftercatheterablationforatrialfibrillationametaanalysisofrandomizedcontrolledtrials
AT zhangdemei blankingperiodantiarrhythmicdrugsaftercatheterablationforatrialfibrillationametaanalysisofrandomizedcontrolledtrials
AT wangxiaomei blankingperiodantiarrhythmicdrugsaftercatheterablationforatrialfibrillationametaanalysisofrandomizedcontrolledtrials
AT guoxueya blankingperiodantiarrhythmicdrugsaftercatheterablationforatrialfibrillationametaanalysisofrandomizedcontrolledtrials